Pajouheshnia R, van Smeden M, Peelen LM, Groenwold RHH. Variation in the measurement of predictors affects the discriminative ability and transportability of a prediction model. Presented at the Methods for Evaluation of Medical Prediction Models, Tests and Biomarkers (MEMTAB) 2018 Symposium; July 2, 2018. Utrecht, The Netherlands. [abstract] Diagn Progn Res. 2018 Jul 2; 2(Suppl 1):40. doi: 10.1186/s41512-018-0036-3
Damen JAAG, Debray TPA, Pajouheshnia R, Reitsma JB, Scholten RJPM, Moons KGM, Hooft L. Empirical evidence on the impact of study characteristics on the performance of prognostic models: a meta-epidemiological study. Presented at the Methods for Evaluation of Medical Prediction Models, Tests and Biomarkers (MEMTAB) 2018 Symposium; July 2, 2018. Utrecht, The Netherlands. [abstract] Diagn Progn Res. 2018 Jul 2; 2(Suppl 1):29-30. doi: 10.1186/s41512-018-0036-3
Pajouheshnia R, Schuster NA, Moons KGM, Rutten FH, Groenwold RHH, Peelen LM. Accounting for time-varying treatments when developing a prognostic model: a case study in patients treated with betablockers. Poster presented at the Methods for Evaluation of Medical Prediction Models, Tests and Biomarkers (MEMTAB) 2018 Symposium; July 2018. Utrecht, Netherlands. [abstract] Diagn Progn Res. 2018 Jul; 2(Supp1):28-9. doi: 10.1186/s41512-018-0036-3
Pajouheshnia R, Damen JAAG, Groenwold RHH, Moons KGM, Peelen LM. Treatment use in prognostic model research: a systematic review of cardiovascular prognostic studies. Diagn Progn Res. 2017 Sep 26;1:15. doi: 10.1186/s41512-017-0015-0
Heus P, Damen JAAG, Pajhouheshnia R, Scholten RJPM, Reitsma JM, Collins GS, Altman DG, Moons KGM, Hooft L. More than half of the TRIPOD items are inadequately reported in prediction modelling studies. Poster presented at the Methods for Evaluating Medical Tests and Biomarkers 2016 Symposium; July 19, 2016. Birmingham, UK. [abstract] Diagn Progn Res. 2017 Feb 16; 1(Suppl 1):27. doi: 10.1186/s41512-016-0001-y
Pajouheshnia R, Groenwold R, Moons K, Reitsma J, Peelen L. The effects of treatment use when externally validating a prediction model that did not include treatment as predictor. Presented at the Methods for Evaluating Medical Tests and Biomarkers 2016 Symposium; February 2016. Birmingham, United Kingdom. [abstract] Diagn Progn Res. 2017 Feb 16; 1(Suppl 1):12. doi: 10.1186/s41512-016-0001-y
Pajouheshnia R, Damen J, Groenwold R, Moons K, Peelen L. How treatment use is addressed in prognostic research: a systematic review. Poster presented at the Methods for Evaluating Medical Tests and Biomarkers 2016 Symposium; July 19, 2016. Birmingham, UK. [abstract] Diagn Progn Res. 2017 Feb 16; 1(Suppl 1):19. doi: 10.1186/s41512-016-0001-y
Damen JAAG, Debray TPA, Heus P, Hooft L, Moons KGM, Pajouheshnia R, Reitsma JB, Scholten RJPM. Design characteristics of external validation studies influencing the performance of risk prediction models. Poster presented at the Methods for Evaluating Medical Tests and Biomarkers 2016 Symposium; July 2016. Birmingham, UK. [abstract] Diagn Progn Res. 2017 Feb 16; 1(Suppl 1):21. doi: 10.1186/s41512-016-0001-y
Damen JAAG, Debray TPA, Heus P, Hooft L, Moons KGM, Pajouheshnia R, Reitsma JB, Scholten RJPM. Performance of the Framingham risk models and pooled cohort equations for the prediction of cardiovascular disease in the general population: a meta-analysis. Poster presented at the Methods for Evaluating Medical Tests and Biomarkers 2016 Symposium; July 19, 2016. Birmington, UK. [abstract] Diagn Progn Res. 2017 Feb 16; 1(Suppl 1):20-1. doi: 10.1186/s41512-016-0001-y
McKenna SP, Doward LC. How should we measure quality of life in ankylosing spondylitis? Rheumatol Pract. 2008;6(2):12-4.